Indivior PLC
INDV
Company Profile
Business description
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
Contact
10710 Midlothian Turnpike
Suite 125
North Chesterfield
RichmondVA23235
USAT: +1 804 379-1040
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,164
Stocks News & Analysis
stocks
Unconventional wisdom: Should I sell this underperforming ASX share?
Going back to my original thesis to evaluate a position.
stocks
Wildly overvalued ASX stock is skating on thin ice
This company dominates its industry and could be flirting with regulatory intervention.
stocks
Uber flexes its network effect and delivers strong result
Uber’s business is humming along but autonomous vehicles add uncertainty to the longer term outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,079.60 | 22.40 | -0.25% |
| CAC 40 | 7,709.32 | 74.29 | 0.97% |
| DAX 40 | 24,192.50 | 268.14 | 1.12% |
| Dow JONES (US) | 43,968.64 | 224.48 | -0.51% |
| FTSE 100 | 9,100.77 | 63.54 | -0.69% |
| HKSE | 24,845.78 | 235.85 | -0.94% |
| NASDAQ | 21,242.70 | 73.27 | 0.35% |
| Nikkei 225 | 41,814.26 | 755.11 | 1.84% |
| NZX 50 Index | 12,844.63 | 42.47 | -0.33% |
| S&P 500 | 6,340.00 | 5.06 | -0.08% |
| S&P/ASX 200 | 8,811.60 | 19.80 | -0.22% |
| SSE Composite Index | 3,636.88 | 2.79 | -0.08% |